Prolonged delivery of peptides

Details Prolonged delivery of peptides Prolonged delivery of peptides

2001-08-31

2004-12-07

Tate, Christopher (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C530S324000

Reexamination Certificate

active

06828303

ABSTRACT:

BACKGROUND OF THE INVENTION
The present invention relates to compositions and methods for the treatment of Diabetes Mellitus. More specifically, the present invention relates to compositions to prolong the administration of glucagon-like peptide 1 (GLP-1), and derivatives thereof. These compositions are useful in treatment of Non-Insulin Dependent Diabetes Mellitus (NIDDM).
The amino acid sequence of GLP-1 is known as:
(SEQUENCE ID NO:1)
His-Asp-Glu-Phe-Glu-Arg-His-Ala-Glu-Gly-Thr-Phe-
Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-
Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly
GLP-1 is disclosed by Lopez, L. C., et al., P.N.A.S., USA 80: 5485-5489 (1983); Bell, G. I., et al., Nature 302: 716-718 (1983); Heinrich, G. et al., Endocrinol. 115: 2176-2181 (1984) and Ghiglione, M., et al., Diabetologia 27: 599-600 (1984).
During processing in the pancreas and intestine, GLP-1 is converted to a 31 amino acid peptide having amino acids 7-37 of GLP-1, hereinafter this peptide is referred to as GLP-1 (7-37).
This peptide has been shown to have insulinotropic activity, that is, it is able to stimulate, or cause to be stimulated, the synthesis or expression of the hormone insulin. Because of this insulinotropic activity, GLP-1 (7-37) is alternatively referred to as insulinotropin.
GLP-1 (7-37) has the following amino acid sequence:
(SEQUENCE ID NO:2)
His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-
Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-
Trp-Leu-Val-Lys-Gly-Arg-Gly.
GLP-1 (7-37), certain derivatives thereof and the use thereof to treat Diabetes mellitus in a mammal are disclosed in U.S. Pat. Nos. 5,118,666 ('666 patent) and 5,120,712 ('712 patent), the disclosures of these patents being incorporated herein by reference. The derivatives of GLP-1 (7-37) disclosed in the '666 and '712 patents include polypeptides which contain or lack one of more amino acids that may not be present in the naturally occurring sequence. Further derivatives of GLP-1 (7-37) disclosed in the '666 and '712 patents include certain C-terminal salts, esters and amides where the salts and esters are defined as OM where M is a pharmaceutically acceptable cation or a lower (C
1
-C
6
) branched or unbranched alkyl group and the amides are defined as —NR
2
R
3
where R
2
and R
3
are the same or different and are selected from the group consisting of hydrogen and a lower (C
1
-C
6
) branched or unbranched alkyl group.
Certain other polypeptides, alternatively referred to as truncated GLP-1 or truncated insulinotropin, having insulinotropic activity and the derivatives thereof are disclosed in PCT/US 89/01121 (WO 90/11296). Those polypeptides, referred to therein as GLP-1 (7-36), GLP-1 (7-35) and GLP-1 (7-34) have the following amino acid sequences, respectively.
(SEQUENCE ID NO:3)
His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-
Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-
Trp-Leu-Val-Lys-Gly-Arg;
(SEQUENCE ID NO:4)
His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-
Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-
Trp-Leu-Val-Lys-Gly; and
(SEQUENCE ID NO:5)
His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-
Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-
Trp-Leu-Val-Lys;
Derivatives of the polypeptides disclosed in PCT/US89/01121 include polypeptides having inconsequential amino acid substitutions, or additional amino acids to enhance coupling to carrier protein or to enhance the insulinotropic effect thereof. Further derivatives of insulinotropin disclosed in PCT/US89/01121 include certain C-terminal salts, esters and amides where the salts and esters are defined as OM where M is a pharmaceutically acceptable cation or a lower branched or unbranched alkyl group and the amides are defined as —NR
2
R
3
where R
2
and R
3
are the same or different and are selected from the group consisting of hydrogen and a lower branched or unbranched alkyl group.


REFERENCES:
patent: 4526938 (1985-07-01), Churchill et al.
patent: 4654324 (1987-03-01), Chance et al.
patent: 4853226 (1989-08-01), Machida et al.
patent: 4857505 (1989-08-01), Arendt
patent: 4942035 (1990-07-01), Churchill et al.
patent: 4985404 (1991-01-01), Mitchell
patent: 4985404 (1991-01-01), Mitchell
patent: 5091185 (1992-02-01), Castillo et al.
patent: 5118666 (1992-06-01), Habener
patent: 5120712 (1992-06-01), Habener
patent: 5156851 (1992-10-01), Castillo et al.
patent: 5175145 (1992-12-01), Cooper
patent: 5232708 (1993-08-01), Castillo et al.
patent: 5424286 (1995-06-01), Eng
patent: 5536508 (1996-07-01), Canal et al.
patent: 5545618 (1996-08-01), Buckley et al.
patent: 5574008 (1996-11-01), Johnson et al.
patent: 5614492 (1997-03-01), Habener
patent: 5631224 (1997-05-01), Efendic et al.
patent: 5700486 (1997-12-01), Canal et al.
patent: 6284727 (2001-09-01), Kim
patent: 0 092 918 (1983-11-01), None
patent: 0 177 478 (1986-04-01), None
patent: 0 263 490 (1988-04-01), None
patent: 0 343 696 (1989-11-01), None
patent: 0 442 671 (1991-08-01), None
patent: 0 462 959 (1991-12-01), None
patent: 0 473 268 (1992-03-01), None
patent: 0 486 959 (1992-05-01), None
patent: 0 526 862 (1993-02-01), None
patent: 0 619 322 (1994-10-01), None
patent: 0 658 568 (1995-06-01), None
patent: 0 733 644 (1996-09-01), None
patent: 4-283510 (1992-10-01), None
patent: WO 87/06941 (1987-11-01), None
patent: WO 88/07366 (1988-10-01), None
patent: WO 90/11296 (1990-10-01), None
patent: WO 91/11457 (1991-08-01), None
patent: WO 93/18785 (1993-09-01), None
patent: WO 93/18786 (1993-09-01), None
patent: WO 93/19175 (1993-09-01), None
patent: WO 93/25579 (1993-12-01), None
patent: WO 95/05848 (1995-03-01), None
patent: WO 95/07098 (1995-03-01), None
patent: WO 95/17510 (1995-06-01), None
patent: WO 95/31214 (1995-11-01), None
patent: WO 96/20005 (1996-07-01), None
patent: WO 97/07814 (1997-03-01), None
Ballard, B.E., “Chapter 91: Prolonged-Action Pharmaceuticals,” inRemington's Pharmaceutical Sciences, 16thEdition, Osol, A. (ed.), Mack Printing Company, Easton, PA, pp. 1594-1613 (1980).
Bell, G.I. et al., “Hamster preproglucagon contains the sequence of glucagon and two related peptides,”Nature 302: 716-718, Macmillan Journals Ltd. (1983).
Biessels, G.-J. et al., “Place Learning and Hippocampal Synaptic Plasticity in Streptozotocin-Induced Diabetic Rats,”Diabetes 45: 1259-1266, The American Diabetes Association (Sep. 1996).
Blackmore, P.F. et al., “Absence of insulinotropic glucagon-like peptide-I (7-37) receptors on isolated rat liver hepatocytes,”FEBS 283:7-10, Federation of European Biochemical Societies and Elsevier Science Publishers B.V. (1991).
Cross, S.E. and Roberts, M.S., “Subcutaneous Absorption Kinetics and Local Tissue Distribution of Interferon and Other Solutes,”J. Pharm. Pharmacol. 45:606-609, Pharmaceutical Press (Jul. 1993).
Deckert, T. et al., “Absorption of NPH-Insulin from Subcutaneous Tissue: A Methodological Study in Pigs,”Acta Pharmacol. Toxicol.(Copenh.) 51:30-37, Munksgaard International Publishers Limited (1982).
Gennaro, A.R., “Chapter 23: Inorganic Pharmaceutical Chemistry,” inRemington's Pharmaceutical Sciences, 16thEdition, Osol, A. (ed.), Mack Publishing Co., Easton, PA, pp. 343-363 (1980).
Ghiglione, M. et al., “How glucagon-like is glucagon-like peptide-1?”Diabetologia 27:599-600, Springer-Verlag (1984).
Gill, I.J. et al., “Cyclodextrins as protection agents against enhancer damage in nasal delivery systems II. Effect on in vivo absorption of insulin and histopathology of nasal membrane,”Eur. J. Pharm. Sci. 1:237-248, Elsevier Science B.V. (Jun. 1994).
Heinrich, G. et al., “Pre-Proglucagon Messenger Ribonucleic Acid: Nucleotide and Encoded Amino Acid Sequences of the Rat Pancreatic Complementary Deoxyribonucleic Acid,”Endocrinology 115:2176-2181, The Endocrine Society (1984).
Hendrick, G.K. et al., “Glucagon-like Peptide-I-(7-37) Suppresses Hyperglycemia in Rats,”Metabolism 42:1-6, W.B. Saunders Company (Jan. 1993).
Hirano, K. and Yamada, H., “Studies on the Absorption of Practically Water-Insoluble Drugs following Injection VIII: Comparison of the Subcutaneous Abs

Affiliated with

Also associated with

Rating

Prolonged delivery of peptides does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Prolonged delivery of peptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Prolonged delivery of peptides will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3294466